Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Tipo de estudo
Intervalo de ano de publicação
1.
Int J Cancer ; 132(2): 297-307, 2013 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-22696308

RESUMO

Serrated adenocarcinoma (SAC) is a recently recognized colorectal cancer (CRC) subtype accounting for 7.5 to 8.7% of CRCs. It has been shown that SAC has a poorer prognosis and has different molecular and immunohistochemical features compared with conventional carcinoma (CC) but, to date, only one previous study has analyzed its mRNA expression profile by microarray. Using a different microarray platform, we have studied the molecular signature of 11 SACs and compared it with that of 15 matched CC with the aim of discerning the functions which characterize SAC biology and validating, at the mRNA and protein level, the most differentially expressed genes which were also tested using a validation set of 70 SACs and 70 CCs to assess their diagnostic and prognostic values. Microarray data showed a higher representation of morphogenesis-, hypoxia-, cytoskeleton- and vesicle transport-related functions and also an overexpression of fascin1 (actin-bundling protein associated with invasion) and the antiapoptotic gene hippocalcin in SAC all of which were validated both by quantitative real-time PCR (qPCR) and immunohistochemistry. Fascin1 expression was statistically associated with KRAS mutation with 88.6% sensitivity and 85.7% specificity for SAC diagnosis and the positivity of fascin1 or hippocalcin was highly suggestive of SAC diagnosis (sensitivity = 100%). Evaluation of these markers in CRCs showing histological and molecular characteristics of high-level microsatellite instability (MSI-H) also helped to distinguish SACs from MSI-H CRCs. Molecular profiling demonstrates that SAC shows activation of distinct signaling pathways and that immunohistochemical fascin1 and hippocalcin expression can be reliably used for its differentiation from other CRC subtypes.


Assuntos
Adenocarcinoma/metabolismo , Biomarcadores Tumorais/metabolismo , Neoplasias Colorretais/metabolismo , Transcriptoma , Adenocarcinoma/diagnóstico , Adenocarcinoma/genética , Adenocarcinoma/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/genética , Proteínas de Transporte/genética , Proteínas de Transporte/metabolismo , Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/genética , Neoplasias Colorretais/mortalidade , Análise Mutacional de DNA , Feminino , Expressão Gênica , Hipocalcina/genética , Hipocalcina/metabolismo , Humanos , Masculino , Proteínas dos Microfilamentos/genética , Proteínas dos Microfilamentos/metabolismo , Instabilidade de Microssatélites , Pessoa de Meia-Idade , Análise Multivariada , Proteína Inibidora de Apoptose Neuronal/genética , Proteína Inibidora de Apoptose Neuronal/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , Oncogenes
2.
Rev. esp. patol ; 43(1): 47-51, ene.-mar. 2010. ilus
Artigo em Espanhol | IBECS | ID: ibc-79248

RESUMO

El hidradenoma nodular maligno o hidradenocarcinoma es un tumor maligno de glándula sudorípara, extremadamente infrecuente, que generalmente surge de novo aunque se han descrito unos pocos casos surgidos sobre un hidradenoma nodular. El comportamiento biológico de este tipo de neoplasias es altamente agresivo con recurrencias locales y metástasis ganglionares en un alto porcentaje.El tratamiento de elección de estos tumores es la escisión quirúrgica con márgenes amplios si bien en la enfermedad metastásica estaría indicado el tratamiento neoadyuvante con quimio y/o radioterapia. Recientemente, se ha propuesto el tratamiento con trastuzumab para los casos con sobreexpresión de Her-2/neu así como la realización de ganglio centinela.Presentamos el caso de un hidradenocarcinoma surgido en un hidradenoma nodular en piel de región intermamaria en una mujer de 55 años. El tumor fue tratado con escisión amplia y se realizó ganglio centinela. La paciente recibió radioterapia posquirúrgica sin que haya evidencia de metástasis tras un año de seguimiento(AU)


Malignant nodular hidradenoma or hidradenocarcinoma is a rare, malignant tumour of sweat glands that usually arises de novo, although a few cases originating in a nodular hidradenoma have been reported. They are very aggressive neoplasms that recur locally and frequently metastasize to the lymph nodes. The treatment of choice is surgical excision with wide margins, followed by chemotherapy and/or radiotherapy when metastases have occurred. Recently, sentinel lymph node sampling and treatment with Trastuzumab have been proposed for cases with overexpression of Her-2/neu. A case of hidradenocarcinoma arising in a nodular hidradenoma of the breast skin of a 55 year old woman is presented. The tumour was surgically removed with a wide excision and the patient treated with postoperative radiotherapy. She is alive and well without evidence of metastatic disease one year later(AU)


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Adenoma de Glândula Sudorípara/complicações , Adenoma de Glândula Sudorípara/diagnóstico , Adenoma de Glândula Sudorípara/terapia , Carcinoma/complicações , Carcinoma/diagnóstico , Neoplasias das Glândulas Sudoríparas/complicações , Neoplasias das Glândulas Sudoríparas/patologia , Glândulas Sudoríparas/patologia , Imuno-Histoquímica/tendências , Imuno-Histoquímica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA